Zapalenie skórno-mięśniowe (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zapalenie skórno-mięśniowe" in Polish language version.

refsWebsite
Global rank Polish rank
4th place
7th place
2nd place
6th place
low place
557th place
1st place
1st place
low place
1,047th place
120th place
180th place
222nd place
228th place
low place
low place
low place
624th place

czytelniamedyczna.pl

doi.org

  • U. Marvi, L. Chung, D.F. Fiorentino. Clinical presentation and evaluation of dermatomyositis. „Indian J Dermatol”. 57 (5), s. 375–381, Sep 2012. DOI: 10.4103/0019-5154.100486. PMID: 23112358. 
  • A.R. Findlay, N.A. Goyal, T. Mozaffar. An overview of polymyositis and dermatomyositis. „Muscle Nerve”. 51 (5), s. 638–656, 2015. DOI: 10.1002/mus.24566. PMID: 25641317. 
  • L. Iaccarino, A. Ghirardello, S. Bettio, M. Zen i inni. The clinical features, diagnosis and classification of dermatomyositis. „J Autoimmun”. 48–49. s. 122–127. DOI: 10.1016/j.jaut.2013.11.005. PMID: 24467910. 
  • A.L. Mammen. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. „Ann N Y Acad Sci”. 1184, s. 134–153, Jan 2010. DOI: 10.1111/j.1749-6632.2009.05119.x. PMID: 20146695. 
  • E.E. Bailey, D.F. Fiorentino. Amyopathic dermatomyositis: definitions, diagnosis, and management. „Curr Rheumatol Rep”. 16 (12), s. 465, 2014. DOI: 10.1007/s11926-014-0465-0. PMID: 25366932. 
  • H. Cao, T.N. Parikh, J. Zheng. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. „Clin Rheumatol”. 28 (8), s. 979–984, 2009. DOI: 10.1007/s10067-009-1152-9. PMID: 19294477. 
  • M. Fathi, I.E. Lundberg, G. Tornling. Pulmonary complications of polymyositis and dermatomyositis. „Semin Respir Crit Care Med”. 28 (4), s. 451–458, 2007. DOI: 10.1055/s-2007-985666. PMID: 17764062. 
  • L. Kao, L. Chung, D.F. Fiorentino. Pathogenesis of dermatomyositis: role of cytokines and interferon. „Curr Rheumatol Rep”. 13 (3), s. 225–232, 2011. DOI: 10.1007/s11926-011-0166-x. PMID: 21318338. 
  • M. Leon-Monzon, M.C. Dalakas. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. „Ann Neurol”. 32 (2), s. 219–222, 1992. DOI: 10.1002/ana.410320215. PMID: 1324633. 
  • M.C. Dalakas, R. Hohlfeld. Polymyositis and dermatomyositis. „Lancet”. 362 (9388), s. 971–982, 2003. DOI: 10.1016/S0140-6736(03)14368-1. PMID: 14511932. 
  • M.C. Dalakas. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. „Curr Opin Pharmacol”. 10 (3), s. 346–352, 2010. DOI: 10.1016/j.coph.2010.03.001. PMID: 20409756. 
  • L.A. Love, C.R. Weinberg, D.R. McConnaughey, C.V. Oddis i inni. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. „Arthritis Rheum”. 60 (8), s. 2499–2504, 2009. DOI: 10.1002/art.24702. PMID: 19644877. 
  • G. Karpati, Y. Pouliot, S. Carpenter. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. „Ann Neurol”. 23 (1), s. 64–72, 1988. DOI: 10.1002/ana.410230111. PMID: 3278673. 
  • P. Englund, E. Lindroos, I. Nennesmo, L. Klareskog i inni. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. „Am J Pathol”. 159 (4), s. 1263–1273, 2001. DOI: 10.1016/S0002-9440(10)62513-8. PMID: 11583954. 
  • C.W. Keller, C. Fokken, S.G. Turville, A. Lünemann i inni. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. „J Biol Chem”. 286 (5), s. 3970–3980, 2011. DOI: 10.1074/jbc.M110.159392. PMID: 20980264. 
  • L.C. Pelosof, D.E. Gerber. Paraneoplastic syndromes: an approach to diagnosis and treatment. „Mayo Clin Proc”. 85 (9), s. 838–854, Sep 2010. DOI: 10.4065/mcp.2010.0099. PMID: 20810794. 
  • J.M. Olazagasti, P.J. Baez, D.A. Wetter, F.C. Ernste. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. „Am J Clin Dermatol”. 16 (2), s. 89–98, Apr 2015. DOI: 10.1007/s40257-015-0120-1. PMID: 25721032. 
  • A.A. Shah, L. Casciola-Rosen, A. Rosen. Review: cancer-induced autoimmunity in the rheumatic diseases. „Arthritis Rheumatol”. 67 (2), s. 317–326, Feb 2015. DOI: 10.1002/art.38928. PMID: 25371098. 
  • C.L. Hill, Y. Zhang, B. Sigurgeirsson, E. Pukkala i inni. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. „Lancet”. 357 (9250), s. 96–100, Jan 2001. DOI: 10.1016/S0140-6736(00)03540-6. PMID: 11197446. [zarchiwizowane z adresu]. 
  • J. Wang, G. Guo, G. Chen, B. Wu i inni. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. „Br J Dermatol”. 169 (4), s. 838–847, Oct 2013. DOI: 10.1111/bjd.12564. PMID: 23909921. 
  • B.J. Distad, A.A. Amato, M.D. Weiss. Inflammatory myopathies. „Curr Treat Options Neurol”. 13 (2), s. 119–130, 2011. DOI: 10.1007/s11940-010-0111-8. PMID: 21222061. 
  • M.C. Dalakas. Immunotherapy of inflammatory myopathies: practical approach and future prospects. „Curr Treat Options Neurol”. 13 (3), s. 311–323, 2011. DOI: 10.1007/s11940-011-0119-8. PMID: 21365201. 
  • I. Marie. Morbidity and mortality in adult polymyositis and dermatomyositis. „Curr Rheumatol Rep”. 14 (3), s. 275–285, 2012. DOI: 10.1007/s11926-012-0249-3. PMID: 22410829. 
  • J.P. Callen, R.L. Wortmann. Dermatomyositis. „Clin Dermatol”. 24 (5). s. 363–373. DOI: 10.1016/j.clindermatol.2006.07.001. PMID: 16966018. 
  • E.H. Choy, J.E. Hoogendijk, B. Lecky, J.B. Winer. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. „Cochrane Database Syst Rev”, s. CD003643, 2005. DOI: 10.1002/14651858.CD003643.pub2. PMID: 16034905. 
  • V. Majithia, V. Harisdangkul. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. „Rheumatology (Oxford)”. 44 (3), s. 386–389, 2005. DOI: 10.1093/rheumatology/keh499. PMID: 15572389. 
  • R.D. Sontheimer. The management of dermatomyositis: current treatment options. „Expert Opin Pharmacother”. 5 (5), s. 1083–1099, 2004. DOI: 10.1517/14656566.5.5.1083. PMID: 15155110. 
  • G.C. Ang, V.P. Werth. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. „Arch Dermatol”. 141 (7), s. 855–859, 2005. DOI: 10.1001/archderm.141.7.855. PMID: 16027300. 
  • N. Miyasaka, M. Hara, T. Koike, E. Saito i inni. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. „Mod Rheumatol”. 22 (3), s. 382–393, 2012. DOI: 10.1007/s10165-011-0534-4. PMID: 21971943. 
  • M.C. Dalakas, I. Illa, J.M. Dambrosia, S.A. Soueidan i inni. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. „N Engl J Med”. 329 (27), s. 1993–2000, 1993. DOI: 10.1056/NEJM199312303292704. PMID: 8247075. 
  • C.V. Oddis, A.M. Reed, R. Aggarwal, L.G. Rider i inni. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. „Arthritis Rheum”. 65 (2), s. 314–324, 2013. DOI: 10.1002/art.37754. PMID: 23124935. 
  • E. Schiopu, K. Phillips, P.M. MacDonald, L.J. Crofford i inni. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. „Arthritis Res Ther”. 14 (1), 2012. DOI: 10.1186/ar3704. PMID: 22284862. 
  • K.H. Yu, Y.J. Wu, C.F. Kuo, L.C. See i inni. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. „Clin Rheumatol”. 30 (12), s. 1595–1601, 2011. DOI: 10.1007/s10067-011-1840-0. PMID: 21915609. 

google.pl

books.google.pl

hudlaeknastodin.is

nih.gov

ncbi.nlm.nih.gov

  • H.R. Briemberg, A.A. Amato. Dermatomyositis and Polymyositis. „Curr Treat Options Neurol”. 5 (5), s. 349–356, 2003. PMID: 12895397. 
  • U. Marvi, L. Chung, D.F. Fiorentino. Clinical presentation and evaluation of dermatomyositis. „Indian J Dermatol”. 57 (5), s. 375–381, Sep 2012. DOI: 10.4103/0019-5154.100486. PMID: 23112358. 
  • M. Auriemma, A. Capo, G. Meogrossi, P. Amerio. Cutaneous signs of classical dermatomyositis. „G Ital Dermatol Venereol”. 149 (5), s. 505–517, 2014. PMID: 25014587. 
  • A.R. Findlay, N.A. Goyal, T. Mozaffar. An overview of polymyositis and dermatomyositis. „Muscle Nerve”. 51 (5), s. 638–656, 2015. DOI: 10.1002/mus.24566. PMID: 25641317. 
  • L. Iaccarino, A. Ghirardello, S. Bettio, M. Zen i inni. The clinical features, diagnosis and classification of dermatomyositis. „J Autoimmun”. 48–49. s. 122–127. DOI: 10.1016/j.jaut.2013.11.005. PMID: 24467910. 
  • A.L. Mammen. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. „Ann N Y Acad Sci”. 1184, s. 134–153, Jan 2010. DOI: 10.1111/j.1749-6632.2009.05119.x. PMID: 20146695. 
  • M.F. van der Meulen, I.M. Bronner, J.E. Hoogendijk, H. Burger i inni. Polymyositis: an overdiagnosed entity. „Neurology”. 61 (3), s. 316–321, Aug 2003. PMID: 12913190. 
  • E.E. Bailey, D.F. Fiorentino. Amyopathic dermatomyositis: definitions, diagnosis, and management. „Curr Rheumatol Rep”. 16 (12), s. 465, 2014. DOI: 10.1007/s11926-014-0465-0. PMID: 25366932. 
  • M.R. Stonecipher, J.L. Jorizzo, W.L. White, F.O. Walker i inni. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis?. „J Am Acad Dermatol”. 28 (6), s. 951–956, 1993. PMID: 8496459. 
  • A. Cosnes, F. Amaudric, R. Gherardi, J. Verroust i inni. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. „Arch Dermatol”. 131 (12), s. 1381–1385, 1995. PMID: 7492125. 
  • H. Cao, T.N. Parikh, J. Zheng. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. „Clin Rheumatol”. 28 (8), s. 979–984, 2009. DOI: 10.1007/s10067-009-1152-9. PMID: 19294477. 
  • M. Fathi, I.E. Lundberg, G. Tornling. Pulmonary complications of polymyositis and dermatomyositis. „Semin Respir Crit Care Med”. 28 (4), s. 451–458, 2007. DOI: 10.1055/s-2007-985666. PMID: 17764062. 
  • L. Kao, L. Chung, D.F. Fiorentino. Pathogenesis of dermatomyositis: role of cytokines and interferon. „Curr Rheumatol Rep”. 13 (3), s. 225–232, 2011. DOI: 10.1007/s11926-011-0166-x. PMID: 21318338. 
  • M. Leon-Monzon, M.C. Dalakas. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. „Ann Neurol”. 32 (2), s. 219–222, 1992. DOI: 10.1002/ana.410320215. PMID: 1324633. 
  • R.L. Leff, L.A. Love, F.W. Miller, S.J. Greenberg i inni. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. „Lancet”. 339 (8803), s. 1192–1195, 1992. PMID: 1349938. 
  • M.C. Dalakas, R. Hohlfeld. Polymyositis and dermatomyositis. „Lancet”. 362 (9388), s. 971–982, 2003. DOI: 10.1016/S0140-6736(03)14368-1. PMID: 14511932. 
  • M.C. Dalakas. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. „Curr Opin Pharmacol”. 10 (3), s. 346–352, 2010. DOI: 10.1016/j.coph.2010.03.001. PMID: 20409756. 
  • L.A. Love, C.R. Weinberg, D.R. McConnaughey, C.V. Oddis i inni. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. „Arthritis Rheum”. 60 (8), s. 2499–2504, 2009. DOI: 10.1002/art.24702. PMID: 19644877. 
  • G. Karpati, Y. Pouliot, S. Carpenter. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. „Ann Neurol”. 23 (1), s. 64–72, 1988. DOI: 10.1002/ana.410230111. PMID: 3278673. 
  • P. Englund, E. Lindroos, I. Nennesmo, L. Klareskog i inni. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. „Am J Pathol”. 159 (4), s. 1263–1273, 2001. DOI: 10.1016/S0002-9440(10)62513-8. PMID: 11583954. 
  • C.W. Keller, C. Fokken, S.G. Turville, A. Lünemann i inni. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. „J Biol Chem”. 286 (5), s. 3970–3980, 2011. DOI: 10.1074/jbc.M110.159392. PMID: 20980264. 
  • L. Behrens, M. Kerschensteiner, T. Misgeld, N. Goebels i inni. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. „J Immunol”. 161 (11), s. 5943–5951, 1998. PMID: 9834075. 
  • D. Di Rollo, D. Abeni, M. Tracanna, A. Capo i inni. Cancer risk in dermatomyositis: a systematic review of the literature. „G Ital Dermatol Venereol”. 149 (5), s. 525–537, Oct 2014. PMID: 24975953. 
  • Y.J. Chen, C.Y. Wu, J.L. Shen. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. „Br J Dermatol”. 144 (4), s. 825–831, Apr 2001. PMID: 11298544. 
  • W. Zhang, S.P. Jiang, L. Huang. Dermatomyositis and malignancy: a retrospective study of 115 cases. „Eur Rev Med Pharmacol Sci”. 13 (2). s. 77–80. PMID: 19499841. 
  • L.C. Pelosof, D.E. Gerber. Paraneoplastic syndromes: an approach to diagnosis and treatment. „Mayo Clin Proc”. 85 (9), s. 838–854, Sep 2010. DOI: 10.4065/mcp.2010.0099. PMID: 20810794. 
  • J.M. Olazagasti, P.J. Baez, D.A. Wetter, F.C. Ernste. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. „Am J Clin Dermatol”. 16 (2), s. 89–98, Apr 2015. DOI: 10.1007/s40257-015-0120-1. PMID: 25721032. 
  • A.A. Shah, L. Casciola-Rosen, A. Rosen. Review: cancer-induced autoimmunity in the rheumatic diseases. „Arthritis Rheumatol”. 67 (2), s. 317–326, Feb 2015. DOI: 10.1002/art.38928. PMID: 25371098. 
  • C.L. Hill, Y. Zhang, B. Sigurgeirsson, E. Pukkala i inni. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. „Lancet”. 357 (9250), s. 96–100, Jan 2001. DOI: 10.1016/S0140-6736(00)03540-6. PMID: 11197446. [zarchiwizowane z adresu]. 
  • J. Wang, G. Guo, G. Chen, B. Wu i inni. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. „Br J Dermatol”. 169 (4), s. 838–847, Oct 2013. DOI: 10.1111/bjd.12564. PMID: 23909921. 
  • A. Sparsa, E. Liozon, F. Herrmann, K. Ly i inni. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. „Arch Dermatol”. 138 (7), s. 885–890, Jul 2002. PMID: 12071815. 
  • B.J. Distad, A.A. Amato, M.D. Weiss. Inflammatory myopathies. „Curr Treat Options Neurol”. 13 (2), s. 119–130, 2011. DOI: 10.1007/s11940-010-0111-8. PMID: 21222061. 
  • M.C. Dalakas. Immunotherapy of inflammatory myopathies: practical approach and future prospects. „Curr Treat Options Neurol”. 13 (3), s. 311–323, 2011. DOI: 10.1007/s11940-011-0119-8. PMID: 21365201. 
  • I. Marie. Morbidity and mortality in adult polymyositis and dermatomyositis. „Curr Rheumatol Rep”. 14 (3), s. 275–285, 2012. DOI: 10.1007/s11926-012-0249-3. PMID: 22410829. 
  • J.P. Callen, R.L. Wortmann. Dermatomyositis. „Clin Dermatol”. 24 (5). s. 363–373. DOI: 10.1016/j.clindermatol.2006.07.001. PMID: 16966018. 
  • S.R. Ytterberg. Treatment of refractory polymyositis and dermatomyositis. „Curr Rheumatol Rep”. 8 (3), s. 167–173, 2006. PMID: 16901073. 
  • E.H. Choy, J.E. Hoogendijk, B. Lecky, J.B. Winer. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. „Cochrane Database Syst Rev”, s. CD003643, 2005. DOI: 10.1002/14651858.CD003643.pub2. PMID: 16034905. 
  • J. Vencovský, K. Jarosová, S. Machácek, J. Studýnková i inni. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. „Scand J Rheumatol”. 29 (2), s. 95–102, 2000. PMID: 10777122. 
  • T.W. Bunch, J.W. Worthington, J.J. Combs, D.M. Ilstrup i inni. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. „Ann Intern Med”. 92 (3), s. 365–369, 1980. PMID: 6986827. 
  • T.W. Bunch. Prednisone and azathioprine for polymyositis: long-term followup. „Arthritis Rheum”. 24 (1), s. 45–48, 1981. PMID: 7008799. 
  • M.G. Danieli, G. Malcangi, C. Palmieri, F. Logullo i inni. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. „Ann Rheum Dis”. 61 (1), s. 37–41, 2002. PMID: 11779756. 
  • V. Majithia, V. Harisdangkul. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. „Rheumatology (Oxford)”. 44 (3), s. 386–389, 2005. DOI: 10.1093/rheumatology/keh499. PMID: 15572389. 
  • R.D. Sontheimer. The management of dermatomyositis: current treatment options. „Expert Opin Pharmacother”. 5 (5), s. 1083–1099, 2004. DOI: 10.1517/14656566.5.5.1083. PMID: 15155110. 
  • G.C. Ang, V.P. Werth. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. „Arch Dermatol”. 141 (7), s. 855–859, 2005. DOI: 10.1001/archderm.141.7.855. PMID: 16027300. 
  • N. Miyasaka, M. Hara, T. Koike, E. Saito i inni. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. „Mod Rheumatol”. 22 (3), s. 382–393, 2012. DOI: 10.1007/s10165-011-0534-4. PMID: 21971943. 
  • M.C. Dalakas, I. Illa, J.M. Dambrosia, S.A. Soueidan i inni. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. „N Engl J Med”. 329 (27), s. 1993–2000, 1993. DOI: 10.1056/NEJM199312303292704. PMID: 8247075. 
  • R. Rios Fernández, J.L. Callejas Rubio, D. Sánchez Cano, J.A. Sáez Moreno i inni. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. „Clin Exp Rheumatol”. 27 (6). s. 1009–1016. PMID: 20149324. 
  • C.V. Oddis, A.M. Reed, R. Aggarwal, L.G. Rider i inni. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. „Arthritis Rheum”. 65 (2), s. 314–324, 2013. DOI: 10.1002/art.37754. PMID: 23124935. 
  • I. Marie, E. Hachulla, P.Y. Hatron, M.F. Hellot i inni. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. „J Rheumatol”. 28 (10), s. 2230–2237, 2001. PMID: 11669162. 
  • E. Schiopu, K. Phillips, P.M. MacDonald, L.J. Crofford i inni. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. „Arthritis Res Ther”. 14 (1), 2012. DOI: 10.1186/ar3704. PMID: 22284862. 
  • K.H. Yu, Y.J. Wu, C.F. Kuo, L.C. See i inni. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. „Clin Rheumatol”. 30 (12), s. 1595–1601, 2011. DOI: 10.1007/s10067-011-1840-0. PMID: 21915609. 

researchgate.net

termedia.pl

web.archive.org

wiley.com

onlinelibrary.wiley.com